Abstract:Evidence suggests that the glycogen synthase kinase 3 (GSK3)-dictated nuclear exclusion and degradation of Nrf2 is pivotal in switching off the self-protective antioxidant stress response after injury. Here, we examined the mechanisms underlying this regulation in glomerular disease. In primary podocytes, doxorubicin elicited cell death and actin cytoskeleton disorganization, concomitant with overactivation of GSK3 beta (the predominant GSK3 isoform expressed in glomerular podocytes) and minimal Nrf2 activation. SB216763, a highly selective small molecule inhibitor of GSK3, exerted a protective effect that depended on the potentiated Nrf2 antioxidant response, marked by increased Nrf2 expression and nuclear accumulation and augmented production of the Nrf2 target heme oxygenase-1. Ectopic expression of the kinase-dead mutant of GSK3 beta in cultured podocytes reinforced the doxorubicin-induced Nrf2 activation and prevented podocyte injury. Conversely, a constitutively active GSK3 beta mutant blunted the doxorubicin-induced Nrf2 response and exacerbated podocyte injury, which could be abolished by treatment with SB216763. In murine models of doxorubicin nephropathy or nephrotoxic serum nephritis, genetic targeting of GSK3 beta by doxycycline-inducible podocyte-specific knockout or pharmacologic targeting by SB216763 significantly attenuated albuminuria and ameliorated histologic signs of podocyte injury, including podocytopenia, loss of podocyte markers, podocyte de novo expression of desmin, and ultrastructural lesions of podocytopathy (such as foot process effacement). This beneficial outcome was likely attributable to an enhanced Nrf2 antioxidant response in glomerular podocytes because the selective Nrf2 antagonist trigonelline abolished the proteinuria-reducing and podocyte-protective effect. Collectively, our results suggest the GSK3 beta-regulated Nrf2 antioxidant response as a novel therapeutic target for protecting podocytes and treating proteinuric glomerulopathies.

Gene deficiency or pharmacological inhibition of PDCD4-mediated FGR signaling protects against acute kidney injury

Genetic and pharmacological inhibition of GRPR protects against acute kidney injury via attenuating renal inflammation and necroptosis

Pretreatment with Granulocyte Colony‐stimulating Factor Attenuated Renal Ischaemia and Reperfusion Injury Via Activation of PI3/Akt Signal Pathway

Progranulin protects against renal ischemia|[sol]|reperfusion injury in mice

Progranulin Protects Against Renal Ischemia/reperfusion Injury in Mice.

Overexpression of PRDM16 attenuates acute kidney injury progression: genetic and pharmacological approaches

Nanoparticle-mediated Klotho Gene Therapy Prevents Acute Kidney Injury to Chronic Kidney Disease Transition Through Regulating PPARα Signaling in Renal Tubular Epithelial Cells

Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3 Beta Reinforces the Nrf2 Antioxidant Defense Against Podocytopathy

DDRGK1-mediated ER-phagy attenuates acute kidney injury through ER-stress and apoptosis

Conditional knockout of TGF-βRII /Smad2 signals protects against acute renal injury by alleviating cell necroptosis, apoptosis and inflammation

Downregulation of G protein–coupled receptor kinase 4 protects against kidney ischemia-reperfusion injury

#6747 ACTIVATION OF GPR120 IMPROVES THE SENESCENCE OF TUBULAR EPITHELIAL CELLS IN SEPTIC ACUTE KIDNEY INJURY

Chromodomain Y-like (CDYL) inhibition ameliorates acute kidney injury in mice by regulating tubular pyroptosis

RG108 attenuates acute kidney injury by inhibiting P38 MAPK/FOS and JNK/JUN pathways

Smad3-Targeted Therapy Protects against Cisplatin-Induced AKI by Attenuating Programmed Cell Death and Inflammation via a NOX4-Dependent Mechanism

Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response

Pharmacological and Genetic Inhibition of Fatty Acid-Binding Protein 4 Alleviated Cisplatin-Induced Acute Kidney Injury

MiR-155 deficiency protects renal tubular epithelial cells from telomeric and genomic DNA damage in cisplatin-induced acute kidney injury

FGF/FGFR2 Protects against Tubular Cell Death and Acute Kidney Injury Involving Erk1/2 Signaling Activation

A Novel Renoprotective Strategy: Upregulation of PD-L1 Mitigates Cisplatin-Induced Acute Kidney Injury

A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury